Evidence reference only. Not medical advice, not a dosing guide, and not a recommendation to use any drug.
Echo The Echo Compendium
<- All drugs
Investigational and unapproved. Findings below describe what trials and reports have observed. Nothing here is an endorsement, a claim of safety or effectiveness, or a clinical recommendation.

Aleniglipron

INVESTIGATIONAL

oral non-peptide small-molecule GLP-1 receptor agonist

4
graded findings
3
effect domains
Evidence spread
High evidence 0Moderate evidence 4Low evidence 0Very low evidence 0

Aleniglipron is shown as an investigational or pipeline evidence record. Findings describe what studies and reports observed; they do not endorse use or establish personal suitability.

Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
Aleniglipron INVESTIGATIONAL
Weight change Decrease
Moderate evidence

Oral non-peptide GLP-1RA (GSBR-1290, Structure Therapeutics). In ACCESS phase 2b (230 adults, obesity/overweight), once-daily aleniglipron at 45/90/120 mg achieved...

Structure Therapeutics press (ACCESS, ACCESS II, 2025-2026); Nature Medicine ACCESS phase... Source
Full findingOral non-peptide GLP-1RA (GSBR-1290, Structure Therapeutics). In ACCESS phase 2b (230 adults, obesity/overweight), once-daily aleniglipron at 45/90/120 mg achieved placebo-adjusted weight loss of -8.2/-9.8/-11.3% at week 36. ACCESS II topline reported placebo-adjusted mean weight loss of 16.3% at the 180 mg dose at 44 weeks - described by the sponsor as the highest weight loss for an oral GLP-1RA to date.
PopulationACCESS phase 2b: 230 adults obesity/overweight, once-daily, 36 wk, placebo-controlled. ACCESS II: phase 2, up to 180 mg, 44 wk
Fundingindustry - Structure Therapeutics (sponsor of record; disclosed)
Scope limitsMECHANISM: oral non-peptide small-molecule GLP-1R agonist, once daily. aleniglipron = GSBR-1290 (Structure Therapeutics). ACCESS phase 2b peer-reviewed (Nature Medicine 2026); ACCESS II 180 mg result is press topline. Highest reported oral GLP-1RA weight loss per sponsor - recorded as observation.
Comparatorsplacebo
Aleniglipron INVESTIGATIONAL
Weight change Decrease
Moderate evidence

ACCESS phase 2b: met primary endpoint with dose-dependent placebo-adjusted weight loss at 36 weeks, no apparent plateau.

Rosenstock J et al. Oral small molecule GLP-1 receptor agonist aleniglipron in people wit... Source
PopulationACCESS phase 2b RCT (NCT06693843), N=230 adults with obesity/overweight (mean BMI 39.5, 54% female); 36 wk double-blind + OLE; once-daily escalated q4w; placebo comparator
Fundingindustry - Structure Therapeutics (via subsidiary Gasherbrum Bio, Inc.)
Scope limitssmall sample (N~230)
Comparatorsplacebo
Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
Aleniglipron INVESTIGATIONAL
Safety signals No change
Moderate evidence

No drug-induced liver injury events reported in the phase 2b trial.

Rosenstock J et al. Oral small molecule GLP-1 receptor agonist aleniglipron in people wit... Source
PopulationACCESS phase 2b (NCT06693843); 36 wk
Fundingindustry - Structure Therapeutics (via subsidiary Gasherbrum Bio, Inc.)
Scope limitssmall sample (N~230)
Comparatorsplacebo
Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
Aleniglipron INVESTIGATIONAL
Gastrointestinal tolerability Increase
Moderate evidence

GI events generally mild-to-moderate and decreased over time; treatment-related discontinuations modest.

Rosenstock J et al. Oral small molecule GLP-1 receptor agonist aleniglipron in people wit... Source
PopulationACCESS phase 2b N=230 (NCT06693843); 36 wk; placebo comparator
Fundingindustry - Structure Therapeutics (via subsidiary Gasherbrum Bio, Inc.)
Scope limitssmall sample (N~230)
Comparatorsplacebo